Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Reexamination Certificate
2005-03-08
2008-10-14
Ouspenski, Ilia (Department: 1644)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
C424S093200
Reexamination Certificate
active
07435596
ABSTRACT:
The present invention relates to novel methods for preferentially activating and expanding NK cells. The methods utilize the stimulatory effects of IL-15 and CD137 ligand to preferentially expand and activate NK cells in a mixed cell culture comprising NK cells.
REFERENCES:
patent: 5359046 (1994-10-01), Capon
patent: 5674704 (1997-10-01), Goodwin
patent: 5686281 (1997-11-01), Roberts
patent: 6103521 (2000-08-01), Capon
patent: 6303121 (2001-10-01), Kwon
patent: 7070995 (2006-07-01), Jensen
Riley et al., Blood, 2005, 105: 13-21.
ATCC No. CCL-243, 1975.
Ishiwata et al., Exp. Pathol., 1991, 41: 1-9; Abstract (1 page).
Greenwald et al., Annu. Rev. Immunol., 2005, 23: 515-548.
Burkett, P.R., et al.; “Coordinate Expression and Trans Presentation of Interleukin (IL)-15Rα and IL-15 Supports Natural Killer Cell and Memory CD8+T Cell Homeostasis”,J. Exp Med 200:825-834 (2004).
Carson, W.E., et al.; “A Potential Role for Interleuing-15 in the Regulation of Human Natural Killer Cell Survival”;J. Clin Invest 99:937-943 (1997).
Cooper, M.A., et al.; “In vivo evidence for a dependence on interleukin 15 for Survival of natural killer cells”;Blood 100: 3633-3638 (2002).
Farag, S.S., et al.; “Natural killer cell receptors: new biology and insights into the Graft-versus-leukemia effect”;Blood 100: 1935-1947 (2002).
Fehniger, T.A. and Caligiuri, M.A.; “Ontogeny and Expansion of Human Natural Killer Cells: Clinical Implications”;Int Rev Immunol 20: 503-534 (2001).
Harada, H., et al.; “Selective Expansion of Human Natural Killer Cells from Peripheral Blood Mononuclear Cells by the Cell Line, HFWT”;Jpn J Cancer Res 93: 313-319 (2002).
Harada, H., et al.; “A Wilms tumor cell line, HFWT, can greatly stimulate proliferation of CD56+ human natural killer cells and their novel precursors in blood mononuclear cells,”;Exp Hem 32: 614-621 (2004).
Klein, E., et al.; “Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia”;Int J Cancer 18: 421-431 (1976).
Lozzio C.B. and Lozzio, B.B.; “Human chronic myelogeneous leukemia cell-line with positive Philadelphia chromosome”;Blood 45:321-334 (1975).
Maus, M.V., et al.; “Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB”;Nat Biotechnology 20:143-148 (2002).
May, K.F., et al.; “Anti-4-1BB Monoclonal Antibody Enhances Rejection of Large Tumor Burden by Promoting Survival by not Clonal Expansion of Tumor-specific CD8+T Cells1”; Cancer Res 62:3459-3465 (2002).
Melero, I., et al.; “Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors”,Nature Med 3: 682-685 (1997).
Melero, I., et al.; “NK1.1 Cells Express 4-1BB (CDw 137) Constimulatory Molecule and Are Required by Tumor Immunity Elicited by Anti-4-1BB Monoclonal Antibodies”;Cell Immun 190:167-172 (1998).
Moretta L. and Moretta A.; “Unravelling natural killer cell function: triggering and inhibitory human NK receptors”;EMBO 23:255-259 (2004).
Robertson, M.J., et al.; “Costimulation of Human Natural Killer Cell Proliferation: Role of Accessory Cytokines and Cell Contact-Dependent Signals”;Nat immune 15:213-226 (1996).
Oelke, M., et al; “Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells”;Nature Medicine 9:619-624 (2003).
Imai, C., et al.; “A novel method for propagating primary natural killer (NK) cells allows highly Efficient expression of anti-CD19 chimeric receptors and generation of powerful cytotoxicity Against NK-resistent acute lymphoblastic leukemia cells.” Abstract # 306Blood 104(Nov. 16, 2004).
Alderson, M.R.; et al., “Molecular and Biological Characterization of Human 4-1BB and its Ligand,”Eur. J. Immunol., 1994, pp. 2219-2227, vol. 24.
Brentjens, R.J., et al., “Eradication of Systemic B-Cell Tumors by Genetically Targeted Human T Lymphocytes Co-Stimulated B Cd80 and Interleukin-15,”Nature Medicine, 2003, pp. 279-286, vol. 9.
Bukczynski, J, et al., “Costimulation of Human CD28- T Cells by 4-1BB Ligand,”Eur. J. Immunol., 2003, pp. 446-454, vol. 33.
Campana, D., et al., “Immunophenotyping of Leukemia,”Jour of Immunol Methods, 2000, pp. 59-75, vol. 243.
Cheung, N-K. V., et al., “Anti-Idiotypic Antibody Facilitates scFv Chimeric Immune Receptor-Gene Transduction and Clonal expansion of Human Lymphocytes for Tumor Therapy,”Hybridoma and Hybridomics, 2003, pp. 209-218, vol. 22(4).
Cooper, L.J., et al., “T-Cell Clones can be Rendered Specific for CD-19: Toward the Selective Augmentation Of the Graft-Versus-B-Lineage Leukemia Effect,”Blood, 2003, pp. 1637-1644, vol. 101.
DeBenedette, MA, et al., “Costimulatin of CD28- T Lymphocytes by 4-1BB Ligand,”J. Immunol., 1997, pp. 551-559, vol. 158.
Eshhar, Z., et al., “Functional Expression of Chimeric Receptor Genes in Human T Cells,”J. Immunol. Methods, 2001, pp. 67-76, vol. 248.
Finney, H.M, et al., “Activation of Resting Human Primary T Cells with Chimeric Receptors: Constimulation from CD28, Inducible Constimulator, CD134, and CD137 in Series with Signals from TCR Chain,”Journ of Immun, 2004, pp. 104-113, vol. 1720.
Geiger, T.L., et al., “Integrated src Kinase and Costimulatory Activity Enhances Signal Transduction through Single-Chain Chimeric Receptors in T Lymphocytes,”Blood, 2001, pp. 2364-2371, vol. 98.
Goodwin, R.G., et al., “Molecular Cloning of a Ligand for the Inducible T Cell Gene 4-1BB: A Member of an Emerging Family of Cytokines with Homology to Tumor Necrosis Factor”,Eur. J. Immunol., 1993, pp. 2631-2641, vol. 23.
Fehniger, T.A., et al., “Ontogeny and Expansion of Human Natural Killer Cells: Clinical Implications,”Int Rev Immunol, 2001, pp. 503-534, vol. 20.
Harada, H., et al., “A Wilms Tumor Cell Line, HFWT, can Greatly Stimulate Proliferation of CD56+ Human Natural Killer Cells and their Novel Precursors in Blood Mononuclear Cells,”Exp. Hematology, 2004, pp. 614-621, vol. 32.
Harada, H., et al., “Selective Expansion of Human Natural Killer Cells from Peripheral Blood Mononuclear Cells B the Cell Line, HFWT,”Jpn. J. Cancer Res., 2002, pp. 313-319, vol. 93.
Haynes, N.M., et al., “Single-Chain Antigen Recognition Receptors that Costimulate Potent Rejection of Established Experimental Tumors,”Blood, 2002, pp. 3155-3163, vol. 100.
Haynes, N.M., et al., “Rejection of Syngeneic Colon Carcinoma by CTLs Expressing Single-chain Antibody Receptors Codeliverin CD28 Costimulation,”J Immunol, 2002, pp. 5780-5786, vol. 169.
Hombach, A., et al., “Tumor-Specific T Cell Activation by Recombinant Immunoreceptors: CD3ζ Signaling and CD28 Costimulation are Simultaneously Required for Efficient IL-2 Secretion and can be Integrated into One Combined Required for Efficient IL-2 Secretion and can be Integrated into One Combined CD28/CD3ζ Signaling Receptor Molecule”,J. Immunol, 2001, pp. 6123-6131, vol. 167.
Hurtado, J.C., et al., “Signals Through 4-1BB are Costimulatory to Previously Activated Splenic T Cells and Inhibit Activation-Inducted Cell Death,”J. Immunol., 1997, pp. 2600-2609, vol. 158.
Kim, Y-J., et al., “Human 4-1BB Regulates CD28 Co-Stimulation to Promote Th1 Cell Responses,”Eur. J. Immunol., 1998, pp. 881-890, vol. 28.
Kim, Y-J., et al., “Novel T Cell Antigen 4-1BB Associates with the Protein Tyrosine Kinase p561ck1,”J Immunol, 1993, pp. 1255-1262, vol. 151.
Klein, E., et al., “Properties of the K562 Cell Fine, Derived from a Patient with Chronic Myeloid Leukemia,”Int. J. Cancer, 1976, pp. 421-431, vol. 18.
Klingemann, H-G., et al., “Ex Vivo Expansion of Natural Killer Cells f
Campana Dario
Imai Chihaya
Alston & Bird LLP
Ouspenski Ilia
St. Jude Children's Research Hospital, Inc.
LandOfFree
Modified cell line and method for expansion of NK cell does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified cell line and method for expansion of NK cell, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified cell line and method for expansion of NK cell will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3996606